Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc
Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
Morgan Stanley analyst Vikram Purohit maintains $Acelyrin(SLRN.US)$ with a hold rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 33.6% and a
Express News | ACELYRIN Inc : Morgan Stanley Cuts Target Price to $6 From $13